GRK2 negatively regulates IGF-1R signaling pathway and cyclins' expression in HepG2 cells

Zhengyu Wei1, Reginald Hurtt, Tina Gu

  • 1Division of Transplantation, Department of Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA. wei-zhengyu@cooperhealth.edu

Insights

Reduced G protein coupled receptor kinase 2 (GRK2) enhances insulin-like growth factor 1 receptor (IGF-1R) signaling in liver cancer cells. However, this GRK2 reduction did not promote cell growth but caused cell cycle arrest.

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Biochemistry

Background:

  • G protein coupled receptor kinase 2 (GRK2) is crucial for regulating signaling pathways and its dysregulation impacts diseases like heart failure, arthritis, and obesity.
  • Previous research indicated that GRK2 overexpression inhibits cancer cell growth.
  • The specific role of GRK2 in cancer, particularly in hepatocellular carcinoma (HCC), requires further elucidation.

Purpose of the Study:

  • To investigate the impact of reduced GRK2 protein levels on the insulin-like growth factor 1 receptor (IGF-1R) signaling pathway in human HCC HepG2 cells.
  • To understand the consequences of GRK2 modulation on HCC cell proliferation and cell cycle progression.

Main Methods:

  • Established a GRK2 knockdown HepG2 cell line using lentiviral vector-mediated short hairpin RNA (shRNA).
  • Stimulated cells with insulin-like growth factor 1 (IGF-1) and analyzed IGF-1R expression, tyrosine phosphorylation, and downstream signaling components (IRS1, Akt).
  • Assessed cell growth and cell cycle distribution (G2/M phase) and quantified cyclin A, B1, and E expression.

Main Results:

  • Reduced GRK2 levels in HepG2 cells led to increased total IGF-1R expression and receptor tyrosine phosphorylation upon IGF-1 stimulation.
  • Knockdown of GRK2 resulted in enhanced tyrosine phosphorylation of IRS1 (at residue 612) and increased Akt phosphorylation, indicating stronger IGF-1R pathway activation.
  • Despite enhanced IGF-1R signaling, GRK2-reduced cells did not exhibit increased proliferation but showed a G2/M phase cell cycle arrest, associated with elevated cyclin A, B1, and E expression.

Conclusions:

  • GRK2 negatively regulates the IGF-1R signaling pathway and cyclin expression in HepG2 cells.
  • GRK2 plays a complex role in HCC, exhibiting contrasting effects on signaling pathways versus cell proliferation.
  • Modulating GRK2 levels offers potential therapeutic insights for HCC, though its precise impact on growth requires nuanced understanding.

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of cells.
Two...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...